Categories Earnings, Health Care

Obalon Therapeutics (NASDAQ: OBLN): Q3 2019 Earnings Snapshot

— Obalon Therapeutics (NASDAQ: OBLN) reported a net loss of $0.61 per share for the third quarter of 2019, vs. $2.14 per share loss expected.

— Third-quarter net loss was $3.7 million, compared to a loss of $6.7 million a year earlier

— Revenue decreased to $0.3 million from $3.0 million in the third quarter of 2018, vs. $1.2 million loss expected

— Cost of revenue was $0.4 million, down from $1.4 million in the same period of last year

— Research and development expense declined sharply to $1.2 million from $2.4 million last year

—  Opened the first company-owned retail treatment center, the Obalon Center for Weight Loss

— Raised $16.6 million in gross proceeds from an equity offering

— Promoted William Plovanic to President and CEO; promoted Nooshin Hussainy to CFO

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips

Also Read:  Applied Materials posts Q2 results above street estimates

Most Popular

MongoDB (MDB) has what it takes to end the losing streak. Here’s why

An innovative product portfolio that is capable of outshining the legacy databases has helped MongoDB (NASDAQ: MDB) stay largely unaffected by the market turmoil so far. Of late, the database

Macy’s (M) confirms Q1 loss; expects gradual sales recovery

Retailer Macy's (NYSE: M) posted mixed results for its first quarter of 2020. While the topline missed the market's estimates, bottom line topped the targets. There were no change in

STZ Earnings: Key quarterly highlights that you need to know from Constellation Brands Q1 financial results

Constellation Brands (NYSE: STZ) today announced its first quarter financial results for the period ended May 31, 2020. First quarter net loss was $177.9 million, or $0.94 per share, compared

Top